The Motley Fool
21 Mar 2026, 23:49 UTC · 30w ago
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Impact · against what's priced in
Biohaven presents an asymmetric upside play driven by upcoming late-stage clinical readouts in obesity, immunology, and epilepsy. While the company faces high historical losses, its $322 million cash position and recent institutional buying suggest a stable runway to reach these catalysts.
- BHVN+0.40
No priced-in read yet
- In context
The company is shifting focus toward three late-stage programs with meaningful readouts expected this year, supported by a $322 million cash reserve that mitigates immediate liquidity concerns despite a $739 million annual loss.
Read from the article alone
